ATE422494T1 - Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung - Google Patents

Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung

Info

Publication number
ATE422494T1
ATE422494T1 AT00978215T AT00978215T ATE422494T1 AT E422494 T1 ATE422494 T1 AT E422494T1 AT 00978215 T AT00978215 T AT 00978215T AT 00978215 T AT00978215 T AT 00978215T AT E422494 T1 ATE422494 T1 AT E422494T1
Authority
AT
Austria
Prior art keywords
pyridazines
inhibiting effect
substituted pyridines
angiogenesis inhibiting
angiogenesis
Prior art date
Application number
AT00978215T
Other languages
German (de)
English (en)
Inventor
Jacques Dumas
Teddy JOE
Harold Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert Sibley
Ning Su
Stephen Boyer
Julie Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE422494T1 publication Critical patent/ATE422494T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT00978215T 1999-09-28 2000-09-26 Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung ATE422494T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (1)

Publication Number Publication Date
ATE422494T1 true ATE422494T1 (de) 2009-02-15

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978215T ATE422494T1 (de) 1999-09-28 2000-09-26 Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung

Country Status (35)

Country Link
EP (1) EP1228063B1 (show.php)
JP (1) JP4919567B2 (show.php)
KR (3) KR100890473B1 (show.php)
CN (3) CN100422173C (show.php)
AR (3) AR025752A1 (show.php)
AT (1) ATE422494T1 (show.php)
AU (1) AU782820B2 (show.php)
BG (1) BG65860B1 (show.php)
BR (1) BRPI0014382B8 (show.php)
CA (1) CA2385817C (show.php)
CO (1) CO5200835A1 (show.php)
CZ (1) CZ304767B6 (show.php)
DE (1) DE60041548D1 (show.php)
DO (1) DOP2000000070A (show.php)
EE (1) EE05258B1 (show.php)
ES (1) ES2320525T3 (show.php)
GT (1) GT200000158A (show.php)
HR (1) HRP20020308A2 (show.php)
HU (1) HU230223B1 (show.php)
IL (3) IL148880A0 (show.php)
MA (1) MA25563A1 (show.php)
MX (1) MXPA02003156A (show.php)
MY (3) MY135058A (show.php)
NO (1) NO20021520L (show.php)
NZ (1) NZ518589A (show.php)
PA (1) PA8503201A1 (show.php)
PE (1) PE20010607A1 (show.php)
PL (1) PL205957B1 (show.php)
RS (1) RS50369B (show.php)
RU (1) RU2260008C2 (show.php)
SK (1) SK287417B6 (show.php)
TW (1) TW593315B (show.php)
UA (1) UA75053C2 (show.php)
WO (1) WO2001023375A2 (show.php)
ZA (1) ZA200202760B (show.php)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000874A (es) * 2000-08-09 2003-06-06 Astrazeneca Ab Compuestos quimicos.
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
AU2004218914A1 (en) * 2003-03-11 2004-09-23 Novartis Ag Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases
EP1616576A4 (en) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE HEMMER
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030947A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CA2648957A1 (en) 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
AU2007252506C1 (en) 2006-05-18 2012-07-19 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
CN107129502B (zh) 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
DE69533057T2 (de) * 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
BR9912938B1 (pt) * 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
EP1165085B1 (en) * 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Also Published As

Publication number Publication date
PL366342A1 (en) 2005-01-24
NZ518589A (en) 2005-03-24
AU1569601A (en) 2001-04-30
AR082232A2 (es) 2012-11-21
CN100374435C (zh) 2008-03-12
DE60041548D1 (de) 2009-03-26
KR20020038775A (ko) 2002-05-23
MY135058A (en) 2008-01-31
CN100422173C (zh) 2008-10-01
PA8503201A1 (es) 2002-08-26
CA2385817A1 (en) 2001-04-05
AR025752A1 (es) 2002-12-11
BG65860B1 (bg) 2010-03-31
BRPI0014382B8 (pt) 2021-05-25
AU782820B2 (en) 2005-09-01
HUP0202704A3 (en) 2003-12-29
CO5200835A1 (es) 2002-09-27
MXPA02003156A (es) 2002-09-30
HRP20020308A2 (en) 2004-06-30
KR20080091505A (ko) 2008-10-13
WO2001023375A3 (en) 2002-05-02
HK1091819A1 (zh) 2007-01-26
IL193367A (en) 2011-03-31
IL193368A (en) 2011-05-31
HUP0202704A2 (hu) 2002-12-28
CN1769283A (zh) 2006-05-10
EE05258B1 (et) 2010-02-15
MA25563A1 (fr) 2002-10-01
DOP2000000070A (es) 2002-02-28
NO20021520L (no) 2002-05-23
HK1091818A1 (zh) 2007-01-26
IL148880A0 (en) 2002-09-12
TW593315B (en) 2004-06-21
SK5912002A3 (en) 2003-01-09
JP2003526632A (ja) 2003-09-09
BR0014382B1 (pt) 2014-04-01
KR100895572B1 (ko) 2009-04-29
AR082231A2 (es) 2012-11-21
KR100890473B1 (ko) 2009-03-26
BG106637A (bg) 2003-02-28
KR100895571B1 (ko) 2009-04-29
WO2001023375A2 (en) 2001-04-05
CA2385817C (en) 2010-05-04
IL193368A0 (en) 2009-02-11
EP1228063B1 (en) 2009-02-11
RS50369B (sr) 2009-11-10
ZA200202760B (en) 2003-10-29
ES2320525T3 (es) 2009-05-25
CN100422172C (zh) 2008-10-01
MY143377A (en) 2011-05-13
RU2260008C2 (ru) 2005-09-10
IL193367A0 (en) 2009-02-11
KR20080086547A (ko) 2008-09-25
CZ20021444A3 (cs) 2002-08-14
CZ304767B6 (cs) 2014-10-08
HRP20020308B1 (show.php) 2013-01-31
GT200000158A (es) 2002-03-16
NO20021520D0 (no) 2002-03-26
UA75053C2 (en) 2006-03-15
EE200200161A (et) 2003-08-15
BR0014382A (pt) 2003-06-24
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
CN1420879A (zh) 2003-05-28
PL205957B1 (pl) 2010-06-30
PE20010607A1 (es) 2001-07-12
HU230223B1 (en) 2015-10-28
YU22902A (sh) 2004-12-31
MY143580A (en) 2011-05-31
SK287417B6 (sk) 2010-09-07
JP4919567B2 (ja) 2012-04-18

Similar Documents

Publication Publication Date Title
ATE422494T1 (de) Substituierte pyridine und pyridazine mit angiogenesis hemmender wirkung
DE69923869D1 (de) Substituierte pyridine mit herbizider wirkung
DE69826841D1 (de) Phthalazines mit angiogenesis-hemmender wirkung
ATE330953T1 (de) Substituirte pyridine mit herbizider wirkung
ATE194832T1 (de) 2-aryl-substituierte pyridine
ATE249437T1 (de) Substituierte pyridine als selektive cyclooxygenase inhibitoren
ATE381556T1 (de) Pyridin-derivate mit ikb-kinase (ikk-beta) hemmender wirkung
AU4562001A (en) Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
ATE309988T1 (de) Neue pyridin- und quinolin-derivate
DE59710981D1 (de) Heterocyclisch kondensierte Pyridine als CETP Inhibitoren
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
NO995340L (no) Ukonsolidert soneisolasjon og styring
ATE265448T1 (de) Substituierte pyridazinen und kondensierte pyridazinen mit angiogenesis-inhibierender wirkung
GB2372035B (en) Pyridine derivatives and complexes thereof
DE69837621D1 (de) Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel
ATE236124T1 (de) Herbizide 2,6-disubstituierte pyridine und 2,4- disubstituierte pyrimidine
AU2002364102A8 (en) Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
DE59102729D1 (de) Substituierte Pyridine.
DK1068194T3 (da) PDE IV-hæmmende pyridinderivater
DK1380297T3 (da) Orale sammensætninger med 8-chlor-6,11-dihydro-11(4-piperidyliden)-5H-benzo[5,6]-cyklo-hepta[1,2-b]pyridin
PT1149096E (pt) N-oxidos de piridina triciclicos agonistas de vasopressina
ATE271554T1 (de) Phenyl- und pyridyl-tetrahydro-pyridine mit tnf inhibitorischer wirkung
GB9810542D0 (en) Pyrazine and pyridine derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties